Quidel Q2 Revenues Up 6 Percent | GenomeWeb

NEW YORK (GenomeWeb) — Quidel said after the close of the market Tuesday that second quarter revenues rose 6 percent to $31.5 million compared to $29.7 million in the second quarter of 2013.

The increase in revenue was due to greater sales of infectious disease products in the second quarter of 2014, as well as growth in all other product segments, the company said.

In the quarter ended June 30, the company generated $3.8 million in total influenza product sales, the result of a 49 percent increase in international influenza orders.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.